Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
This review will examine the evidence for the effectiveness of these drugs in NAFLD.

Authors' conclusions
Study finds that the insulin-sensitiser pioglitazone, as a treatment for non-alcoholic fatty liver disease (NAFLD), shows some improvements in liver histology and other parameters but the newer agents, the glucagon-like peptide-1 analogues, may be more worthy of future trials. The review suggests that the non-alcoholic steatohepatitis stage of NAFLD is most in need of drug trials.

Project page URL
http://www.hta.ac.uk/2288

URL for DARE abstract
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=12012000160& UserID=0

Indexing Status
Subject indexing assigned by CRD

MeSH
Fatty Livers; Hypoglycemic Agents; Insulin; Insulin Resistance

Language Published
English

Country of organisation
England

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32011000631

Date abstract record published
01/06/2011